Related Experiment Video

Updated: Aug 15, 2026

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors
12:03

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors

Published on: June 7, 2016

Expanded role for ARBs in cardiovascular and renal disease? Recent observations have far-reaching implications

T M Ramahi1

  • 1Section of Cardiovascular Medicine, Yale University School of Medicine, New Haven, Connecticut, USA. ramahi@aya.yale.edu

Postgraduate Medicine
|April 25, 2001
PubMed

Insights

Angiotensin II Receptor Blockers (ARBs) show promise in treating cardiovascular diseases by blocking AT1 receptors. Ongoing trials will clarify their role in cardiovascular and renal conditions.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Angiotensin II Receptor Blockers (ARBs) represent a novel drug class targeting cardiovascular diseases.
  • These drugs selectively inhibit the angiotensin II type 1 (AT1) receptor.

Purpose of the Study:

  • To explore the therapeutic potential of ARBs in cardiovascular disease.
  • To evaluate the efficacy of ARBs in hypertension, ventricular hypertrophy, heart failure, coronary artery disease, and chronic nephropathy.

Main Methods:

  • Review of existing data and theoretical benefits of ARBs.
  • Focus on the mechanism of action involving AT1 receptor blockade.

Main Results:

  • ARBs are effective antihypertensive agents.
  • Potential benefits include prevention/regression of ventricular hypertrophy.
  • ARBs appear safe and well-tolerated in patients with congestive heart failure (CHF).

Conclusions:

  • ARBs may improve survival and reduce morbidity in CHF patients.
  • ARBs might enhance clinical outcomes in coronary artery disease and chronic nephropathy.
  • Further clinical trials are necessary to establish the definitive role of ARBs in cardiovascular and renal disease management.

More Related Videos

Evaluation of Vascular Control Mechanisms Utilizing Video Microscopy of Isolated Resistance Arteries of Rats10:28

Evaluation of Vascular Control Mechanisms Utilizing Video Microscopy of Isolated Resistance Arteries of Rats

Published on: December 5, 2017

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis08:21

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis

Published on: October 26, 2020

Related Concept Videos

Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Aortic Regurgitation III: Medical Management01:25

Aortic Regurgitation III: Medical Management

Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...